ArticleRSC advances2022
Novel derivatives of eugenol as potent anti-inflammatory agents
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Fabrication of Hybrid Alginate Hydrogel Beads Reinforced with Activated Carbon and Evaluation of Their Potential for Controlled Eugenol Release.Pharmaceutics · 2026Article
- Antibacterial Agent-Loaded, Novel In Situ Forming Implants Made with Poly(Isosorbide Sebacate) and Dimethyl Isosorbide as a Solvent for Periodontitis Treatment.Molecules (Basel, Switzerland) · 2025Article
- Development and evaluation of clove oil nanoemulsion-based topical cream for anti-inflammatory activity in mice.Frontiers in veterinary science · 2025Article
- Novel PPAR-γ agonists as potential neuroprotective agents against Alzheimer's disease: rational design, synthesisRSC advances · 2024Article
- Possible Combinatorial Utilization of Phytochemicals and Extracellular Vesicles for Wound Healing and Regeneration.International journal of molecular sciences · 2024Review
- Spicing Up Meat Preservation:Foods (Basel, Switzerland) · 2024Review
- From clove oil to bioactive agents: synthetic routes, antimicrobial and antiparasitic activities of eugenol derivatives.Future medicinal chemistry · 2024Review
- Synthesis, anti-amoebic activity and molecular docking simulation of eugenol derivatives againstSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Novel Derivatives of Eugenol as a New Class of PPARγ Agonists in Treating Inflammation: Design, Synthesis, SAR Analysis and In Vitro Anti-Inflammatory Activity.Molecules (Basel, Switzerland) · 2023Article
- An Update on the Therapeutic Anticancer Potential ofMolecules (Basel, Switzerland) · 2023Review
- MAPLE Processed Nanostructures for Antimicrobial Coatings.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eugenol is a natural product abundantly found in clove buds known for its pharmacological activities such as anti-inflammatory, antidiabetic, antioxidant, and anticancer activities. It is well known from the literature that peroxisome proliferator-activated receptors (PPARγ) have been reported to regulate inflammatory responses. In this backdrop, we rationally designed semi-synthetic derivatives of eugenol with the aid of computational studies, and synthesized, purified, and analyzed four eugenol derivatives as PPARγ agonists. Compounds were screened for PPARγ protein binding by time-resolved fluorescence (TR-FRET) assay. The biochemical assay results were favorable for 1C which exhibited significant binding affinity with an IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.